The genomic landscape of baseline tumor biopsies in this trial spanned the spectrum of genes and pathways (RTK, MAPK, PI3K/AKT/mTOR, cell cycle, and ER pathways) known to be associated with resistance to CDK4/6 inhibitors and endocrine therapy (Fig. 2). Here, MTOR is linked to neoplasm.